<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45169">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01831726</url>
  </required_header>
  <id_info>
    <org_study_id>CTKI258AUS26</org_study_id>
    <nct_id>NCT01831726</nct_id>
  </id_info>
  <brief_title>Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib</brief_title>
  <acronym>SIGNATURE</acronym>
  <official_title>Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 2 - Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Including Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this signal seeking study is to determine whether treatment with dovitinib
      (TKI258) demonstrates sufficient efficacy in select pathway-activated solid tumors and/or
      hematologic malignancies to warrant further study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II, open label study to determine the efficacy and safety of treatment with
      dovitinib (TKI258) in patients with a diagnosis of select solid tumors or hematological
      malignancies that have been pre-identified (prior to study consent) to have mutations,
      translocations or pathway activations inhibited by dovitinib and whose disease has
      progressed on or after standard treatment.

      Genomic profiling is becoming more accessible to patients and their physicians. As such,
      more patients have been identified with potentially-actionable mutations, translocations or
      pathway-activations but do not have access to targeted drug treatment. This is a
      signal-seeking study to match patients with tumor pathway activations inhibited by dovitinib
      to the RTK inhibitor dovitinib. Pre-identification of mutations, translocations, or tumor
      pathway activations inhibited by dovitinib will be performed locally at a CLIA certified
      laboratory prior to participation on the trial.

      Once the patient has been identified, treating physicians who are qualified investigators
      may contact Novartis to consider enrollment in this study. For the purpose of this study,
      genomic profiling is not considered part of screening. Informed consent must be signed
      before any screening activities take place. Once eligibility (screening criteria met) has
      been confirmed by Novartis, the patient will initiate therapy with dovitinib single-agent.
      The patient may not receive any additional anti-cancer therapy during treatment with
      dovitinib.

      Patients will continue to receive study treatment until disease progression (assessed by
      RECIST 1.1 or appropriate hematologic response criteria), unacceptable toxicity, death or
      discontinuation from study treatment for any other reason (e.g., withdrawal of consent,
      start of a new anti-neoplastic therapy or at the discretion of the investigator), otherwise
      known as End of Treatment. All patients who discontinue from study treatment due to disease
      progression must have their progression clearly documented.

      Disease assessment (by RECIST 1.1 or appropriate hematological response assessment criteria)
      will be performed every 8 weeks (Â±4 days) after first dose of study drug (Day 1 of every odd
      cycle), until disease progression or end of treatment, whichever occurs first.  The
      frequency of disease assessment may be reduced to every 12 weeks for patients who have at
      least 4 post-baseline disease assessments and are clinically stable (except AML patients).
      Scans will be assessed locally by the investigator.  After discontinuation of treatment,
      patients, regardless of reason for treatment discontinuation, will be followed for safety
      for 30 days after the last dose.

      All patients will be followed for survival status every 3 months for 2 years after the last
      patient has enrolled in the study,regardless of treatment discontinuation reason (except if
      consent is withdrawn or patient is lost to follow-up)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Clinical benefit associated with dovitinib treatment</measure>
    <time_frame>Week 16</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical benefit rate for patients with solid tumors will be assessed using RECIST 1.1 and will include responses of CR or PR or SD. For hematologic tumors other appropriate hematological response criteria will apply.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response (OR) of Partial Response (PR) or greater</measure>
    <time_frame>baseline and every 8 weeks until disease progression or end of treatment, assessed up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall Response (OR) of Partial Response (PR) or greater based on local investigator assessment. For patients with solid tumors, the assessment criteria will be RECIST 1.1 and will include responses of CR and/or PR. For hematologic tumors other appropriate hematological response criteria will apply and are included in the appendices.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>every 8 weeks until death, assessed up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Progression free survival (PFS) is defined as the time from the date of first dose to the date of first documented disease progression or relapse or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>every 8 weeks until death, assessecd up to 36 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall survival (OS) is defined as the time from the date of first dose to the date of death due to any cause. If a patient is not known to have died, survival time will be censored at the date of the last contact</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>baseline and every 8 weeks until disease progression or end of treatment, assessed up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The duration of response (PR or greater) applies only to patients whose best response was PR or greater. It is defined as the time from the first documented response to the date first documented disease progression or relapse or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>more than 30 days after the last date of study treatment, assessed up to 24 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety and tolerability will be will be based on the frequency of adverse events and on the number of laboratory values that fall outside of pre-determined ranges. Other safety data (e.g., electrocardiogram, vital signs) will be considered as appropriate</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Tumor Pathway Activations Inhibited by Dovitinib</condition>
  <arm_group>
    <arm_group_label>Dovitinib (TKI258)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dovitinib (TKI) will be dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule. A</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dovitinib (TKI258)</intervention_name>
    <description>Dovitinib (TKI) will be dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule.</description>
    <arm_group_label>Dovitinib (TKI258)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has a confirmed diagnosis of a select solid tumor (except primary diagnosis
             of urothelial tumors, hepatocellular carcinoma (HCC), endometrial carcinoma,
             metastatic breast cancer (mBC), squamous non-small cell lung cancer (NSCLC), and
             renal cell carcinoma (RCC)) or hematologic malignancies (except primary diagnosis of
             FLT3 AML or multiple myeloma) and is in need of treatment because of progression or
             relapse. Additional tumor types may be excluded during the course of the study in the
             case of early futility or success based upon an interim analysis.

          -  Patient's tumor has been evaluated and pre-identified with a relevant pathway
             activation inhibited by dovitinib at a CLIA certified laboratory

          -  Patient must have received at least one prior treatment for recurrent, metastatic and
             /or locally advanced disease and for whom no standard therapy options are anticipated
             to result in a durable remission.

          -  Patient must have progressive and measurable disease as per RECIST 1.1. or other
             appropriate hematological guidelines.

          -  Patient has an Eastern Cooperative Oncology Group (ECOG) performance status â¤ 1

        Exclusion Criteria:

          -  Patient has received prior treatment with dovitinib (TKI258)

          -  Patients with brain metastasis or history of brain metastasis or leptomeningeal
             carcinomatosis

          -  Patient has received chemotherapy or targeted anticancer therapy â¤ 4 weeks (6 weeks
             for nitrosourea, antibodies or mitomycin-C) prior to starting study drug.

          -  Patient is currently receiving prasugrel, clopidogrel, or full dose anticoagulation
             treatment with therapeutic doses of warfarin. However, treatment with low doses of
             warfarin (e.g., â¤2 mg/day) or locally accepted low doses of acetylsalicylic acid (up
             to 100 mg daily) to prevent cardiovascular events or strokes is allowed.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Enrollment Call Center</last_name>
    <phone>1-855-744-6727</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Highlands Oncology Group SC</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>479-872-8130</phone>
    </contact>
    <investigator>
      <last_name>Joseph T. Beck</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PCR Oncology</name>
      <address>
        <city>Pismo Beach</city>
        <state>California</state>
        <zip>93449</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>805-474-9143</phone>
    </contact>
    <investigator>
      <last_name>David Palchak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarcoma Oncology Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>310-522-9999</phone>
    </contact>
    <investigator>
      <last_name>Sant Chawla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers Rocky Mountain Cancer Centers</name>
      <address>
        <city>Greenwood Village</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>303-388-4876</phone>
    </contact>
    <investigator>
      <last_name>Allen Cohn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Whittingham Cancer Center Norwalk Hospital</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06856</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>203-852-2996</phone>
    </contact>
    <investigator>
      <last_name>Richard C. Frank</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists Florida Cancer Specialists (31</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>561-366-4100</phone>
    </contact>
    <investigator>
      <last_name>Daniel L. Spitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Cancer &amp; Blood Center, LLC</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>706-353-2990</phone>
    </contact>
    <investigator>
      <last_name>Petros Nikolinakos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NorthWest Georgia Oncology Centers Marietta Center</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>770-281-5100</phone>
    </contact>
    <investigator>
      <last_name>Robert C. Hermann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southeastern Regional Medical Center</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30265</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>770-400-6000</phone>
    </contact>
    <investigator>
      <last_name>Navneet Dhillon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University Developmental Therapeutics Ins</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>312-695-0184</phone>
    </contact>
    <investigator>
      <last_name>Melissa Johnson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Care</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615-7828</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>309-243-3000</phone>
    </contact>
    <investigator>
      <last_name>James A Knost</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Indiana Univ. - Purdue Univ.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>317-278-8845</phone>
    </contact>
    <investigator>
      <last_name>Bert O'Neil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Int. Medicine Oncology</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>734-647-8903</phone>
    </contact>
    <investigator>
      <last_name>Aijai Shivaram Alva</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology, P.A. Minnesota Oncology Hematology</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>612-884-6300</phone>
    </contact>
    <investigator>
      <last_name>Timothy G. Larson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Billings Clinic Onc Dept</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>406-435-7484</phone>
    </contact>
    <investigator>
      <last_name>Roger G Santala</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada CCC of Nevada- Southwest (2)</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>702-952-2158</phone>
    </contact>
    <investigator>
      <last_name>Wolfram Samlowski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center Dept of Oncology</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>551-996-5098</phone>
    </contact>
    <investigator>
      <last_name>Martin E. Gutierrez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Cleveland Clinic (19)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>216-444-8258</phone>
    </contact>
    <investigator>
      <last_name>Davendra Sohal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bend Memorial Clinic Bend Mem. Clinic</name>
      <address>
        <city>Bend</city>
        <state>Oregon</state>
        <zip>97701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>541-318-3137</phone>
    </contact>
    <investigator>
      <last_name>William G. Schmidt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>503-494-8534</phone>
    </contact>
    <investigator>
      <last_name>Matthew Taylor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The West Clinic</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>901-683-0055</phone>
    </contact>
    <investigator>
      <last_name>Daruka Mahadevan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>615-329-7274</phone>
    </contact>
    <investigator>
      <last_name>David R. Spigel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Austin Cancer Centers Austin Cancer Center (2)</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>512-334-2851</phone>
    </contact>
    <investigator>
      <last_name>Brian Shimkus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A. SC</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75251</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>512-421-4100</phone>
    </contact>
    <investigator>
      <last_name>Morris Groves</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Consultants Oncology Group</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>832-824-5383</phone>
    </contact>
    <investigator>
      <last_name>Julio Peguero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center/University of Texas MD Anderson Cancer Center (3)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>713-745-0147</phone>
    </contact>
    <investigator>
      <last_name>Sarina Piha-Paul</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tyler Cancer Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>903-579-9800</phone>
    </contact>
    <investigator>
      <last_name>Donald A. Richards</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center Intermountain Healthcare</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>435-688-4900</phone>
    </contact>
    <investigator>
      <last_name>Lincoln Nadauld</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alexander Spira</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties Hematology/Oncology</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>253-383-3366</phone>
    </contact>
    <investigator>
      <last_name>Sibel Blau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yakima Valley Memorial Hospital North Star Lodge</name>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <zip>98902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>509-574-3493</phone>
    </contact>
    <investigator>
      <last_name>Thomas Boyd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora Research Institute</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>414-778-4345</phone>
    </contact>
    <investigator>
      <last_name>Michael A. Thompson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin Cancer Ctr.-Froedtert Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>414-805-4600</phone>
    </contact>
    <investigator>
      <last_name>Karen-Sue Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.signaturetrial.com</url>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 2, 2014</lastchanged_date>
  <firstreceived_date>April 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid tumor malignancy</keyword>
  <keyword>hematologic malignancy</keyword>
  <keyword>mutation</keyword>
  <keyword>translocations</keyword>
  <keyword>FGFR</keyword>
  <keyword>PDGFR</keyword>
  <keyword>VEGF</keyword>
  <keyword>cKIT</keyword>
  <keyword>FLT3</keyword>
  <keyword>CSR1</keyword>
  <keyword>Trk</keyword>
  <keyword>RET</keyword>
  <keyword>TKI258</keyword>
  <keyword>dovitinib</keyword>
  <keyword>signature</keyword>
  <keyword>AML</keyword>
  <keyword>acute myelogenous leukemia</keyword>
  <keyword>GIST</keyword>
  <keyword>gastrointestinal stromal tumor</keyword>
  <keyword>Head and Neck cancer</keyword>
  <keyword>Melanoma</keyword>
  <keyword>NSCLC</keyword>
  <keyword>non-small cell lung carcinoma</keyword>
  <keyword>lung cancer</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>thyroid cancer</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
